Modafinil is a wake-promoting compound with low abuse potential used in the treatment of narcolepsy. Although the compound is reported to affect multiple neurotransmitter systems such as catecholamines, serotonin, glutamate, GABA, orexin, and histamine, however, the molecular mechanism by which modafinil increases wakefulness is debated. Herein we used dopamine ( 
Introduction
Modafinil [(diphenyl-methyl)-sulfinyl-2-acetamide; Modiodal, Provigil] is a novel wake-promoting agent first marketed in France in the early 1990s and currently approved by the United States Food and Drug Administration to treat excessive daytime sleepiness associated with narcolepsy, shift-work sleep disorder, and obstructive sleep apnea/hypopnea syndrome (Zeitzer et al., 2006; Minzenberg and Carter, 2008) . Modafinil acts differently from established psychostimulants (Lin et al., 1992) and possesses only minimal potential for abuse (Jasinski, 2000; DerocheGamonet et al., 2002; Rao et al., 2007) . However, the mechanism of modafinil-induced wakefulness is controversial.
Several hypotheses were suggested for modafinil's mechanism of action by in vivo and in vitro studies. Modafinil can increase catecholamine, serotonin, and glutamate release, and decrease GABA release in various brain regions (for review, see Minzenberg and Carter, 2008) , as well as activate orexin-containing hypothalamic neurons (Chemelli et al., 1999) and the histaminergic tuberomammillary nucleus (TMN) (Scammell et al., 2000) . To date, the only central neurotransmitter elements to which modafinil has been demonstrated to bind directly are the dopamine (DA) transporter (DAT) and norepinephrine (NE) transporter (NET), whereas no apparent specific binding to a range of other monoamine or neuropeptide receptors or transporters or nerve membrane ion channels has been reported (Mignot et al., 1994) . The effects of modafinil on catecholamine are proposed to be primary, with those on other systems seemingly being secondary to the effects on DA and/or NE (Minzenberg and Carter, 2008) .
Although some studies suggested that modafinil increases wakefulness by activating central noradrenergic transmission (Duteil et al., 1990; Lin et al., 1992; Stone et al., 2002) , this hypothesis produced several unresolved questions about the role of noradrenergic systems in modafinil-induced wakefulness: mainly why modafinil does not affect the peripheral sympathetic system (Duteil et al., 1990) and why in narcoleptic patients and dogs modafinil effectively treats excessive daytime sleepiness but fails to prevent the loss of muscle tone (Billiard et al., 1994; Shelton et al., 1995; Nishino and Mignot, 1997; Nishino et al., 1998) . In addition, pharmacological elimination of the NET-bearing forebrain projections in mice did not influence the efficacy of modafinil action (Wisor and Eriksson, 2005) . On the other hand, modafinil enhances extracellular levels of DA in the nucleus accumbens and prefrontal cortex and increases wakefulness in rats (de Saint Hilaire et al., 2001; Murillo-Rodríguez et al., 2007) . Inhibition of DAT increases extracellular levels of DA, which activates its receptors to regulate the sleep-wake cycle. Wisor et al. (2001) reported that modafinil does not induce wakefulness in DAT knock-out (KO) mice. However, Jones et al. (1999) and Fauchey et al. (2000) have found that DAT KO mice have downregulation of the D 1 receptor (D 1 R) and D 2 R, opening up the question of whether the reduction in the response was attributable to reduction in receptor levels. Therefore, the role of dopaminergic systems and DA receptors in modafinil-induced wakefulness remains unclear.
D 1 R and D 2 R are the most widely and abundantly expressed receptors for DA in the brain (Kobayashi et al., 2004) . Because double-KO mice for D 1 R and D 2 R do not survive to the age required for electroencephalogram (EEG) recording (Kobayashi et al., 2004 ), here we used D 2 R KO mice in conjunction with DA receptor antagonists and found that D 1 R and D 2 R are essential for the arousal effect of modafinil.
Materials and Methods
Animals. D 2 R KO and wild-type (WT) mice of the inbred C57BL/6 strain were generated from heterozygotes (Yamaguchi et al., 1996) and maintained at Oriental Bioservice. Male D 2 R KO mice and their WT littermates, weighing 20 -26 g (11-13 weeks old), were used in these experiments. The animals were housed in an insulated sound-proof recording room maintained at an ambient temperature of 22 Ϯ 0.5°C with a relative humidity of 60 Ϯ 2% on an automatically controlled 12 h light/12 h dark cycle (light on at 8:00 A.M.) and had ad libitum access to food and water. Experimental protocols were approved by the Animal Care Committee of Osaka Bioscience Institute. Every effort was made to minimize the number of animals used and any pain and discomfort experienced by them.
Pharmacological treatments. Modafinil (Sigma-Aldrich) was dissolved in sterile PBS containing 10% DMSO and 2% (w/v) cremophor immediately before use and administered intraperitoneally at 10:00 A.M. on the experimental day at doses of 22.5, 45, 90, and 180 mg/kg. R-(ϩ)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1 H-3-benzazepine (SCH23390) (Sigma-Aldrich), a selective D 1 R antagonist, and raclopride (Sigma-Aldrich), a selective D 2 R antagonist, were dissolved in sterile saline and administered intraperitoneally 30 min before the injection of modafinil. For baseline data, mice were injected intraperitoneally with vehicle only at 9:30 and 10:00 A.M.
Polygraphic recordings and vigilance state analysis. Under pentobarbital anesthesia (50 mg/kg, i.p.), mice were chronically implanted with EEG and electromyogram (EMG) electrodes for polysomnographic recordings. The implant consisted of two stainless-steel screws (1 mm diameter) inserted through the skull of the cortex (anteroposterior, ϩ1.0 mm; leftright, Ϫ1.5 mm from bregma or lambda) according to the atlas of Franklin and Paxinos (1997) and served as EEG electrodes. Two insulated stainless-steel, Teflon-coated wires bilaterally placed into both trapezius muscles served as EMG electrodes. All electrodes were attached to a microconnector and fixed to the skull with dental cement.
The recordings of EEG and EMG were performed by means of a slip ring, designed so that the behavioral movement of the mice would not be restricted. After a 10 d recovery period, the mice were housed individually in transparent barrels and habituated to the recording cable for 3-4 d before polygraphic recording. Sleep-wakefulness states were monitored for a period of 48 h, which comprised baseline and experimental days. Baseline recordings were taken in each animal for 24 h, beginning at 8:00 A.M., which served as the control for the same animal.
Cortical EEG and EMG signals were amplified and filtered (EEG, EMG, and then digitized at a sampling rate of 128 Hz and recorded by using SleepSign (Kissei Comtec) as described previously (Huang et al., 2001 Qu et al., 2006) . When complete, polygraphic recordings were automatically scored off-line by 10 s epochs as wakefulness, rapid eye movement (REM), and non-REM (NREM) sleep by SleepSign according to standard criteria (Huang et al., 2001 Qu et al., 2006; Kohtoh et al., 2008) . As a final step, defined sleep-wake stages were examined visually and corrected if necessary.
Statistical analysis. All results were expressed as means Ϯ SEM. For the time course data, amounts of the different sleep-wake states were analyzed by the paired t test, with each animal serving as its own control. For the total amounts of each vigilance stage for 9 h after drug treatment, one-or two-way repeated-measures ANOVA followed by the Fisher's probable least-squares difference (PLSD) test was used to determine whether the difference among groups and genotypes was statistically significant. In all cases, p Ͻ 0.05 was taken as the level of significance.
Results

D 1 R antagonist blocked arousal effects of low-dose modafinil, but did not affect it when modafinil was given at 90 and 180 mg/kg
To investigate the contribution of D 1 R and D 2 R to the arousal effects of modafinil, we administered D 1 R antagonist SCH23390 Figure 2 . A-C, Total time of WT mice spent in wakefulness and in NREM and REM sleep for 9 h after modafinil administration (A) or pretreatment with D 1 R antagonist SCH23390 (B) or D 2 R antagonist raclopride (C). Open and filled bars show the profiles for the baseline and experimental days, when the mice were treated with vehicle (for baseline day) or with modafinil or modafinil plus the indicated DA receptor antagonist (for experimental day). Modafinil was given at 10:00 A.M., and pretreatment with D 1 R or D 2 R antagonist was given at 9:30 A.M. on the experimental day. Values are the means Ϯ SEM (n ϭ 6 -8). *p Ͻ 0.05, **p Ͻ 0.01 compared with its own control, by two-way ANOVA, followed by the PLSD test.
(30 g/kg) or D 2 R antagonist raclopride (2 mg/kg) at 9:30 A.M., followed by modafinil administration at 10:00 A.M. into C57BL/6 WT mice. The dosages for SCH23390 and raclopride were selected based on previous reports (Ongini et al., 1993; Simon et al., 1995) .
Time course changes in wakefulness showed that the arousal effects caused by intraperitoneal modafinil at doses of 22.5, 45, 90, and 180 mg/kg lasted for 2, 3, 5, and 9 h, respectively, compared with the wake time for the vehicle control ( Fig. 1 A-D) . During the wakefulness, no NREM or REM sleep episodes appeared. This enhancement of wakefulness was concomitant with decreases in NREM and REM sleep (data not shown). There was no further disruption of sleep architecture during the subsequent light period, but a decrease in wakefulness during the subsequent dark periods was observed in the groups treated with modafinil at 45, 90, and 180 mg/kg.
Pretreatment with the D 1 R antagonist SCH23390 at a dose of 30 g/kg 30 min before administration of modafinil completely abolished the arousal effects of modafinil at 22.5 mg/kg and significantly attenuated them when modafinil was injected at 45 mg/kg ( Fig.  1 E, F ) . However, when given at 90 and 180 mg/kg, pretreatment with this antagonist did not lessen the wakefulness at all (Fig.  1G,H ) . Because the highest dose of modafinil (180 mg/kg) induced wakefulness for 9 h, we calculated the total amount of wakefulness after modafinil administration. Compared with the vehicle control, modafinil at 22.5, 45, 90, and 180 mg/kg significantly increased wakefulness by 1.2-, 1.4-, 1.7-, and 2.4-fold, concomitant with a significant decrease in NREM sleep by 13, 22, 45, and 96%, respectively. As to REM sleep, modafinil at 22.5 mg/kg did not alter it for 9 h, whereas given at 45, 90, and 180 mg/kg, the drug did reduce REM sleep by 32, 51, and 98%, respectively. Modafinil at 11.25 mg/kg did not change the sleep-wake profiles ( Fig.  2A) . Pretreatment with the D 1 R antagonist abolished wakefulness caused by modafinil at 22.5 and 45 mg/kg. However, modafinil at doses of 90 and 180 mg/kg after D 1 R antagonist administration increased wakefulness by 1.2-and 2.5-fold, with a concomitant decrease in NREM by 48 and 98%, respectively, and one in REM sleep by 43 and 99%, respectively, compared with the vehicle control (Fig. 2B) . These findings indicate that modafinil administered to WT mice rapidly and significantly increased the wake time in a dose-dependent manner and that the D 1 R antagonist could block arousal effects of modafinil at low dosages, but not at doses Ͼ90 mg/kg. D 2 R antagonist blocked the arousal effect of low-dose modafinil and attenuated the effects of modafinil at 90 or 180 mg/kg As shown in Figure 1 , pretreatment of WT mice with the D 2 R antagonist raclopride at 2 mg/kg completely abolished the wakefulness caused by low-dose modafinil at 22.5 and 45 mg/kg (Fig. 1 I, J ) and decreased to 3 and 5 h the wakefulness caused by modafinil at 90 and 180 mg/kg, respectively ( Fig.  1 K, L) . The antagonist pretreatment concomitantly decreased NREM sleep by 25 and 36%, respectively, and REM sleep by 32 and 61%, respectively, which are half the amounts of wakefulness obtained with modafinil administration only (Fig. 2 A, C) . These findings indicate that both D 1 R and D 2 R are involved in modafinil-induced wakefulness, with D 2 R having preferential importance. time spent in wakefulness, compared with the vehicle control (Fig. 3A) . When administered at 45, 90, and 180 mg/kg, however, modafinil induced wakefulness for 3, 5, and 9 h, respectively, in WT mice ( Fig.  1 B-D) , but it did so just for 1, 3, and 6 h, respectively, in the D 2 R KO mice (Fig.  3B-D) .
The total time spent in wakefulness and NREM and REM sleep for 9 h after administration was also determined. There was no essential difference in the amounts of wakefulness and NREM and REM sleep in response to vehicle versus modafinil administration at 22.5 and 45 mg/kg in D 2 R KO mice. Modafinil at 90 and 180 mg/kg increased wakefulness by 1.2 and twofold, respectively, during 9 h after administration, lower than the increase by 1.7-and 2.4-fold in WT mice (Fig. 4 A) . These findings, similar to those obtained from the WT mice pretreated with the D 2 R antagonist, indicate that the mice genetically deficient in D 2 R mimicked the attenuating effect of the drug on wakefulness in WT mice pretreated with the D 2 R antagonist.
Blockade of D 1 R in D 2 R KO mice completely abolished modafinil-induced wakefulness
There are no D 1 R and D 2 R double-KO mice available for sleep recording because these mutants do not survive to the second or third week after birth and are severely growth-retarded (Kobayashi et al., 2004) . We pharmacologically blocked D 1 R and observed the arousal effects of modafinil in D 2 R KO mice. In WT mice, pretreatment with the D 1 R antagonist SCH23390 (30 g/kg) did not affect the arousal effects of modafinil given at 90 and 180 mg/kg, because it increased the total amount of wakefulness during that 9 h period by 1.9-or 2.5-fold, respectively, the same effects as found for modafinil administration only. However, the arousal effect of modafinil at 22.5, 45, 90, or 180 mg/kg was completely antagonized (Fig. 3E-H ) , and also the amounts of NREM and REM sleep remained unchanged (Fig.  4 B) in D 2 R KO mice pretreated with the D 1 R antagonist. These results clearly indicate that D 1 R and D 2 R act cooperatively or synergistically in the wakefulness-promoting effect of modafinil.
Effects of D 1 R and D 2 R on wake duration after modafinil administration
Wake duration is defined as the time from the injection of modafinil or vehicle to the appearance of the first NREM sleep episode lasting for at least 20 s . As shown in Figure 5 , the modafinil-induced continuous wakefulness for 9 h at 180 mg/kg in WT mice (Fig. 5B ) was shortened to 5 h in either D 2 R KO mice (Fig. 5F ) or in WT mice pretreated with a D 2 R antagonist (Fig. 5D) , and completely abolished by pretreatment of D 2 R KO mice with the D 1 R antagonist (Fig. 5G) .
Modafinil given at 22.5, 45, 90, and 180 mg/kg increased the duration of wakefulness relative to that of the vehicle alone by 2.6-, 4.1-, 6.3-, and 13.5-fold, respectively, in WT mice, and by 1.1-, 1.9-, 3.7-, and 10.1-fold, respectively, in D 2 R KO mice (Fig.  6 A, C) . Pretreatment of WT mice with the D 1 R antagonist blocked wakefulness by modafinil at 22.5 and 45 mg/kg, but modafinil at 90 and 180 mg/kg still increased wakefulness (Fig.  6 B) in these mice; however, when pretreated with D 1 R antagonist in D 2 R KO mice, modafinil-induced wakefulness was completely abolished (Fig. 6 D) .
Discussion
Genetic and pharmacological studies on the molecular mechanisms underlying modafinil-induced wakefulness revealed that D 1 R and D 2 R are essential to the mediation of the arousal effect of modafinil. Concomitant activation of D 1 R and D 2 R is also crucial in the control of other physiological functions regulated by DA (Aizman et al., 2000) . For example, double-KO mice for D 1 R and D 2 R do not survive to the second or third week after birth. These mutants are severely growth-retarded with altered feeding behavior and dysfunction of the gastrointestinal system, suggesting the interrelationship between D 1 and D 2 receptor-mediated control of motor activity, food intake, and gastrointestinal functions (Kobayashi et al., 2004) . Similarly, modafinil's effects on cognition is probably mediated by these two receptors (Minzenberg and Carter, 2008) . These results indicate the presence of cooperative/synergistic functional interactions between D 1 R and D 2 R.
Pretreatment of D 2 R KO mice with D 1 R antagonist completely abolished modafinil-induced wakefulness, indicating that DA plays an important role in arousal effect of modafinil. Modafinil effects on wakefulness has been reported to be abolished in DAT KO mice (Wisor et al., 2001) , in which D 2 autoreceptor or function also appears severely impaired (Jones et al., 1999) . mRNA levels of both the D 1 R and D 2 R are also demon- Figure 4 . A, B, Total time spent in wakefulness and in NREM and REM sleep for 9 h after modafinil administration (A) and pretreatment with D 1 R antagonist before modafinil (B) to D 2 R KO mice. On the experimental day, modafinil was given at 10:00 A.M., and pretreatment with the D 1 R antagonist was given at 9:30 A.M. The vehicle was used on the baseline day. Each value is presented as the mean Ϯ SEM (n ϭ 6 -8). *p Ͻ 0.05, **p Ͻ 0.01, significantly different from the control, as assessed by one-way ANOVA followed by the PLSD test.
strated to be decreased in DAT KO mice (Fauchey et al., 2000) . The sole role of DAT in the arousal effect of modafinil is not easily explained considering the fact that maintenance of the modafinil wake-promoting action occurs in cats treated with an inhibitor of catecholamine synthesis (Lin et al., 1992) . These findings suggested that impairment of D 1 R and D 2 R may also contribute to the abolishment of modafinil wakefulness in DAT KO mice.
The D 1 R is a postsynaptic receptor and D 2 R has two variants, a short form and a long form, representing presynaptic autoreceptors and postsynaptic receptors, respectively (Usiello et al., 2000) . Dopamine-containing cells of the substantia nigra pars compacta and the ventral tegmental area (VTA) do not express D 1 R mRNA (Weiner et al., 1991) , whereas the D 2 R has been characterized on neuron cell bodies and dendrites in the substantia nigra pars compacta and the VTA, where it serves an autoreceptor function (Missale et al., 1998) . D 1 R is coupled to adenylate cyclase, and its stimulation facilitates the activity of the enzyme. Dopamine receptors corresponding to the D 2 subfamily are coupled to the inhibition of adenylate cyclase (Monti and Monti, 2007 ). An earlier study found no effects of modafinil on the activity of mesencephalic DA single units in rats (Akaoka et al., 1991) , whereas a recent study found that in rat brain slices, modafinil (20 M) inhibits the activity of VTA DA neurons, with this effect abolished by D 2 R antagonist sulpiride, blunted by DA reuptake blocker nomifensine and unaffected by ␣1-adrenoreceptor blocker prazosin (Korotkova et al., 2007) . These latter findings are consistent with modafinil inhibition of DA reuptake, leading to increased activation of the DA cell body autoreceptor to diminish DA cell firing. However, the derived current-voltage relationships for modafinil-evoked versus nomifensine-evoked currents showed a very different reversal potential in response to these two agents, suggesting that modafinil may exert its action in this preparation at a site distinct from the DAT. These in vitro studies led the authors to propose a potential agonistic action of modafinil on the D 2 R (Korotkova et al., 2007) .
The involvement of the D 2 R is an attractive hypothesis, because it could explain a number of findings that are not easily explained by the DAT inhibition hypothesis. Increased serotonin release would be expected because of the excitatory function of D 2 R on dorsal raphe serotonin neurons (Haj-Dahmane, 2001 ). Modafinil reduces the outflow of GABA in cortex, striatum, and posterior hypothalamus as measured by microdialysis (Ferraro et al., 1996 (Ferraro et al., , 1998 . Inhibition of GABA release in the striatum (Ferraro et al., 1998) can be easily attributed to D 2 R activation. GABA release in the posterior hypothalamus may promote sleep via inhibition of the TMN (Hong et al., 2005) , and a reduction in GABAergic activity could disinhibit these hypothalamic regions, resulting in increased wakefulness.
Modafinil does increase fos immunoreactivity in identified orexin cells in the perifornical area of mice and rats (Chemelli et al., 1999; Scammell et al., 2000) . However, modafinil induces wakefulness more potently in orexin KO mice than in WT mice, with similar patterns of fos immunoreactivity (Willie et al., 2005) . In addition, modafinil does not bind the orexin 1 receptor (Wieland et al., 2002) and retains effects on both extracellular striatal DA and wake-promoting activity in orexin 2 receptor-deficient narcoleptic dogs (Wisor et al., 2001) . Histaminergic systems play an important role in orexin-induced wakefulness (Huang et al., 2001 (Huang et al., , 2007 . Although modafinil also activates fos expression in the TMN, which contains wake-promoting histaminergic neurons (Scammell et al., 2000) , and both intraperitoneal and intracerebroventricular administration of modafinil elevate extracellular histamine in the anterior hypothalamus, direct injection of modafinil into the TMN does not affect histamine release (Ishizuka et al., 2003) , and arousal effects still appeared in the mice lacking the histamine synthesis enzyme histidine decarboxylase, and therefore lacking histamine in the CNS (Parmentier et al., 2007) . Therefore, activation of orexin and histamine systems may be secondary effects to the wakefulness caused by modafinil.
D 2 R KO mice exhibit only minor changes in DA synthesis and metabolism, with normal extracellular DA levels (Dickinson et al., 1999 ). An immunocytochemistry study found an increased staining for DAT in the striatum of D 2 R KO mice (Parish et al., 2001 ). Autoradiography using [ 3 H]SCH23390 revealed no qualitative regional differences in the distribution of D 1 R binding sites in the brains of D 2 R KO mice, including ventral striatum and frontal cortex (Kelly et al., 1998) . Behaviorally, D 2 R KO mice exhibited a normal circadian profile of sleep-wake cycle (Fig. 3) but with an increase in NREM sleep during dark periods (data not shown). Although circadian rhythmicity was normal, D 2 R KO mice showed a markedly deficient light-masking response, indicating that D 2 R-mediated signaling is an essential component of the neuronal pathways leading to light masking of circadian rhythms (Doi et al., 2006) .
In conclusion, we found that either D 1 R or D 2 R antagonist blocked the arousal effects of low-dose modafinil at 22.5 and 45 mg/kg. When modafinil given at 90 and 180 mg/kg, D 1 R antagonist did not effectively affect high-dose modafinil-induced wakefulness but D 2 R antagonist significantly attenuated it. D 2 R KO mice exhibited the similar effect of WT mice pretreated with a D 2 R antagonist. Pretreatment of D 2 R KO mice with a D 1 R antagonist completely abolished the arousal effects of modafinil. These findings strongly indicate that D 1 R and D 2 R are essential for the arousal effect of modafinil, with D 2 R being the receptor of primary importance.
